✓ Translated by DotMD AI Clinical Council Source: BMC cancer • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #36585629 ↗

Phase III Randomized Trial: A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases (N = 88)

Original Paper Title: “A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 88
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Protocol version 1.0 (January 31, 2020). Alberta Health Services, Edmonton, Canada (Samir Patel, MD).
  • Study Design & Sample: Phase III Randomized Trial published in BMC cancer (N = 88 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in BMC cancer (2022), this phase iii randomized trial evaluating 88 human participants investigated: Postoperative stereotactic radiosurgery (SRS) is a standard management option for patients with resected brain metastases. Key clinical takeaway: Protocol version 1.0 (January 31, 2020). Alberta Health Services, Edmonton, Canada (Samir Patel, MD).

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (BMC cancer, 2022-12-30; N = 88; Rigor 82/100): Protocol version 1.0 (January 31, 2020). Alberta Health Services, Edmonton, Canada (Samir Patel, MD).

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: surgery → Condition: spleen-enlargement-splenomegaly → Condition: palate-edema →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36585629: Phase III Randomized Trial: A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases (N = 88)

3 of 3 Free Questions Remaining